In this context, RERF peptide which, able to interfere with the invasive phenotype of ovarian cancer cells by inhibiting uPAR84-95-triggered, FPR-mediated signals, could be considered a valid prototype for the development of new anti-neoplastic therapies designed to simultaneously counteract growth and abdominal dissemination of ovarian cancer cells. The gene discussed is FPR1; the disease is ovarian cancer.